Assessment of a HER2 scoring system for gastric cancer:: results from a validation study

被引：961

作者：

Hofmann, M. ^{[2
]}

Stoss, O. ^{[1
]}

Shi, D. ^{[3
]}

Buettner, R. ^{[1
,4
]}

van de Vijver, M. ^{[5
]}

Kim, W. ^{[6
]}

Ochiai, A. ^{[7
]}

Rueschoff, J. ^{[1
,2
]}

Henkel, T.

机构：

[1] TARGOS Mol Pathol GmbH, D-34125 Kassel, Germany

[2] Klinikum Kassel, Inst Pathol, Kassel, Germany

[3] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China

[4] Univ Hosp Bonn, Inst Pathol, Bonn, Germany

[5] Netherlands Canc Inst, Amsterdam, Netherlands

[6] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea

[7] Natl Canc Ctr, Res Inst E, Div Pathol, Chiba, Japan

来源：

HISTOPATHOLOGY | 2008年 / 52卷 / 07期

关键词：

fluorescence in situ hybridization; gastric cancer; HER2; immunohistochemistry; trastuzumab;

D O I：

10.1111/j.1365-2559.2008.03028.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Aims: Human epidermal growth factor receptor 2 (HER2) overexpression/amplification is implicated in the development of various solid tumour types. Validated methods and scoring systems for evaluating HER2 status exist in breast cancer, but not in gastric cancer. The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrolment in a trial of trastuzumab (Herceptin((R))) in advanced metastatic gastric cancer. Methods and results: Formalin-fixed paraffin-embedded gastric cancer samples were tested for HER2 status using the fluorescence in situ hybridization (FISH) pharmDx (TM) kit (Dako Denmark A/S). Immunohistochemistry (IHC) was performed using the HercepTest (TM) (Dako). Concordance between FISH and IHC was 93.5% in 168 evaluable samples. Eleven samples were scored as FISH+ but IHC- or equivocal. Conclusions: IHC/FISH discrepancies were attributed to basolateral membranous immunoreactivity of glandular cells resulting in incomplete membranous reactivity and/or a higher rate of tumour heterogeneity in gastric cancer compared with breast cancer. With modifications to the IHC scoring system, the HercepTest (TM) is considered valid for the identification of HER2+ gastric tumours for this clinical trial. Correlation of HER2 scores with clinical outcomes will be needed to determine which patients might benefit from trastuzumab therapy.

引用

页码：797 / 805

页数：9

共 40 条

[1] c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems [J].